Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Daniel S. Chen"'
Autor:
Prasad S. Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Thomas W. Dubensky, Elizabeth Evans, Jane L. Grogan, Bryan A. Irving, Rom S. Leidner, Shane A. Olwill, Patrick Soon-Shiong, Frederic Triebel, David Tuck, Adrian Bot, Roger D. Dansey, Charles G. Drake, Gordon J. Freeman, Ramy Ibrahim, Salil Patel, Daniel S. Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Abstract This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor,
Externí odkaz:
https://doaj.org/article/5bb5a295fe6b4f3fa973a3c47fce0e74
Autor:
Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke, Mario Sznol, Konstanty Korski, Suzanne Jones, Genevive Hernandez, James Mier, Xian He, F. Stephen Hodi, Mitchell Denker, Vincent Leveque, Marta Cañamero, Galina Babitski, Hartmut Koeppen, James Ziai, Neeraj Sharma, Fabien Gaire, Daniel S. Chen, Daniel Waterkamp, Priti S. Hegde, David F. McDermott
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combinat
Externí odkaz:
https://doaj.org/article/6805535216ff4aaca60ddedaf5252687
Autor:
James L Gulley, James Larkin, Leisha A Emens, Mario Sznol, Madhav Dhodapkar, Daniel S Chen, Roy S Herbst, Tim F Greten, Robert L Ferris, Luca Mazzarella, Paolo A Ascierto, Marc S Ernstoff, Michael B Atkins, Kim A Margolin, Brian I Rini, Michael R Bishop, Suresh S Ramalingam, Meredith M Regan, Rachel W Humphrey
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
The broad activity of agents blocking the programmed cell death protein 1 and its ligand (the PD-(L)1 axis) revolutionized oncology, offering long-term benefit to patients and even curative responses for tumors that were once associated with dismal p
Externí odkaz:
https://doaj.org/article/924c88f5ec8f4838a91c8255c8c43862
Autor:
Daniel S. Chen, Stefan J. Scherer, Rebecca Elliott, Coen Bernaards, Y. Gloria Meng, Nicole F. Li, Dafeng Chen, Adrian M. Jubb, Priti S. Hegde
PDF file - 234K, Baseline demographics for patients with and without VEGF-A samples in the AVF2107, E4599, AVAiL, and AVOREN trials, The GEN.038 VEGF-A ELISA, Standard curves for different VEGF-A isoforms in the GEN.038 assay, Correlation of baseline
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2907964628f99f116fd4205da225951
https://doi.org/10.1158/1078-0432.22448259
https://doi.org/10.1158/1078-0432.22448259
Autor:
F. Stephen Hodi, Priti S. Hegde, Daniel S. Chen, Carol O'Hear, Marcella Fassò, Marcus Ballinger, Indrani Sarkar, John D. Powderly, David F. McDermott, Harriet M. Kluger, Eva Muñoz-Couselo, Jeffrey A. Sosman, Christopher R. Bolen, Luciana Molinero, Omid Hamid
Purpose:Atezolizumab [anti–programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity. We evaluated the long-term safety and act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10746515c079c17f9a6ccbb5603f4804
https://doi.org/10.1158/1078-0432.c.6527925.v1
https://doi.org/10.1158/1078-0432.c.6527925.v1
Autor:
Hartmut Koeppen, Daniel S. Chen, Kenneth J. Hillan, Virginia K. Langmuir, Maike Schmidt, Melody A. Cobleigh, James D. Reimann, Dafeng Chen, Adrian L. Harris, Hope S. Rugo, Kathy D. Miller, Adrian M. Jubb
Purpose: The addition of bevacizumab to cytotoxic chemotherapy has demonstrated a progression-free survival (PFS) benefit in the first-line and second-line treatment of advanced or metastatic breast cancer (MBC). However, the addition of bevacizumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b5f88df21e4a07d7583cd33ddec4620
https://doi.org/10.1158/1078-0432.c.6520133
https://doi.org/10.1158/1078-0432.c.6520133
Autor:
F. Stephen Hodi, Priti S. Hegde, Daniel S. Chen, Carol O'Hear, Marcella Fassò, Marcus Ballinger, Indrani Sarkar, John D. Powderly, David F. McDermott, Harriet M. Kluger, Eva Muñoz-Couselo, Jeffrey A. Sosman, Christopher R. Bolen, Luciana Molinero, Omid Hamid
Figures S1-S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01ed4fcdf75666e00700454e15846c60
https://doi.org/10.1158/1078-0432.22471542
https://doi.org/10.1158/1078-0432.22471542
Autor:
Hartmut Koeppen, Daniel S. Chen, Kenneth J. Hillan, Virginia K. Langmuir, Maike Schmidt, Melody A. Cobleigh, James D. Reimann, Dafeng Chen, Adrian L. Harris, Hope S. Rugo, Kathy D. Miller, Adrian M. Jubb
Supplementary Figures S1-S3; Supplementary Tables S1-S4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a3d1175e530270e39e4f22d54cc6c34
https://doi.org/10.1158/1078-0432.22444337
https://doi.org/10.1158/1078-0432.22444337
Autor:
F. Stephen Hodi, Priti S. Hegde, Daniel S. Chen, Carol O'Hear, Marcella Fassò, Marcus Ballinger, Indrani Sarkar, John D. Powderly, David F. McDermott, Harriet M. Kluger, Eva Muñoz-Couselo, Jeffrey A. Sosman, Christopher R. Bolen, Luciana Molinero, Omid Hamid
Tables S1-S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d649a52c6adc2a7c3b695bdfbc42a0d4
https://doi.org/10.1158/1078-0432.22471545
https://doi.org/10.1158/1078-0432.22471545
Autor:
Daniel S. Chen, Stefan J. Scherer, Rebecca Elliott, Coen Bernaards, Y. Gloria Meng, Nicole F. Li, Dafeng Chen, Adrian M. Jubb, Priti S. Hegde
Purpose: We evaluated the prognostic and predictive use of circulating VEGF-A levels in phase III trials of bevacizumab in colorectal cancer, lung cancer, and renal cell carcinoma.Methods: Baseline plasma samples from 1,816 patients were analyzed for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::526555deac0dd2e9cb5dd450bcc4a290
https://doi.org/10.1158/1078-0432.c.6521346.v1
https://doi.org/10.1158/1078-0432.c.6521346.v1